LDS/Medical Tests/Endomysial (EMA) Antibody, IgA

Endomysial (EMA) Antibody, IgA

Celiac disease (gluten sensitive enteropathy, GSE) is a non-allergic, immune-mediated sensitivity in genetically susceptible individuals to gluten or related proteins present in wheat, barley, and rye. The exact cause is unknown; however, it is a form of malabsorption involving the duodenum, jejunum, and proximal ileum. Development of the disease can happen at any time from infancy to late adulthood. Individuals with this disease develop IgA antibodies to the endomysium after the ingestion of gluten (as well as other autoantibodies). There is also evidence for cell-mediated cytotoxicity and antigen-antibody complex deposition-induced injury via complement activation. Damage to the lining of the small intestines is the most common manifestation of this disease although it can contribute to many other conditions such as anemia, miscarriage, thyroid disease, diabetes, etc.

Tissue transglutaminase (tTG) has been identified as the major target autoantigen of the endomysial antibody (in essence, anti-endomesial antibody is the same thing as anti-tissue transglutaminase antibody since the transglutaminase is present within the endomesium of muscle cells), and those with a family member with the disease are at a greater risk for developing the disease. tTG is an enzyme that catalyzes the replacement of amide groups of protein and peptide-bound glutamine residues by primary amines (cross-linking), as well as by hydrolysis (deamidation). Gliadin, a glutamine-rich protein, has been identified as a specific substrate for tTG. Elimination of gliadin has been reported to improve the overall diagnostic performance of conventional antigliadin antibody assays, and treatment consists of a lifelong gliadin-free diet. Vitamin and mineral supplements are often prescribed to correct any nutritional deficiency due to the special diet. The IgA anti-tTG and anti-deamidated gliadin antibody tests are the most specific and sensitive serologic tests for celiac disease.  Although the IgA EMA test has high specificity for celiac disease (>90%), its negativity is not completely confirmatory because IgA-deficient patients cannot develop these antibodies. In these cases the detection of IgG gliadin and IgG tTG antibodies are helpful in the diagnosis. Positive results should be followed up with small bowel biopsies before and after the elimination of dietary gluten.

  • Diagnosis of celiac disease
  • Differential diagnosis of irritable bowel syndrome
  • As an aid in diagnosis of inflammatory bowel disease
  • As an aid in diagnosis of malabsorption and malnutrition
  • As an aid in differentiation from colorectal cancer

Increased in:

  • Celiac disease
  • Irritable bowel syndrome
  • Inflammatory bowel disease

Negative (Non-reactive)

 

 

Indirect Immunofluorescence, Enzyme Linked Immunosorbent Assay

Serum (SST).

Stability

    • Ambient: 3-5 days
    • Refrigerated: 5-7 days
    • Frozen: 30 days

Preferred panel for celiac disease diagnosis. Panel includes: IgA total, Tissue Transglutaminase Antibodies IgA and IgG, Deamidated Gliadin Peptide (DGP) Antibody IgA, F-Actin (Smooth Muscle) Antibody IgA, Duodenum Biopsy, Skin Biopsy, anti Smooth Muscle Antibody.

1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Mol Diagn Ther. 2008;12(5):289-98. [PMID: 18803427]
  • Scand J Gastroenterol. 2000 Feb;35(2):181-3. [PMID: 10720117]
  • Eur J Gastroenterol Hepatol. 1997 Jun;9(6):559-62. [PMID: 9222726]
  • Clin Endocrinol (Oxf). 2005 Mar;62(3):303-6. [PMID: 15730411]
  • Jacobs DS, DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).